Welcome

Alere to Sell Two Business Lines to Quidel in $400 Million Pact

July 17, 2017, 3:05 PM

Alere Inc. agreed to sell two businesses to Quidel Corp. for about $400 million, helping move the company closer to cinching its merger with Abbott Laboratories.

San Diego-based Quidel is buying Alere’s Triage cardiovascular and toxicology assets as well the device maker’s B-type natriuretic peptide (BNP) blood test, which combined brought in an estimated $197 million in revenue in 2016. Quidel, which expects the deal to close by Sept. 30, also agreed to a potential $40 million in additional payments.

Alere shareholders voted earlier this month to approve an amended merger worth about $5.3 billion with Abbott, ending months of ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.